Wednesday, 02 January 2019 16:49

Heron Therapeutics Featured

Written by 
Rate this item
(0 votes)

Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address major unmet medical needs. Our portfolio includes two products approved by the US Food and Drug Administration, SUSTOL® (granisetron) extended release injection and CINVANTI TM (aprepitant) injectable emulsion, as well as one product in development; HTX-011, a novel fixed-dose combination of the local anesthetic bupivacaine with the nonsteroidal anti- inflammatory drug (NSAID) meloxicam is being investigated for application into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours.

Additional Info

Read 27 times Last modified on Wednesday, 02 January 2019 16:54